CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+14.98%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$787M
AUM Growth
+$273M
(+53%)
Cap. Flow
+$226M
Cap. Flow
% of AUM
28.71%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
459
New
34
Increased
332
Reduced
39
Closed
19
Top Buys
| 1 |
Microsoft
MSFT
|
$18.2M |
| 2 |
NVIDIA
NVDA
|
$11.9M |
| 3 |
Netflix
NFLX
|
$9.94M |
| 4 |
Amazon
AMZN
|
$7.89M |
| 5 |
Meta Platforms (Facebook)
META
|
$7.84M |
Top Sells
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.64M |
| 2 |
Walmart
WMT
|
$3.08M |
| 3 |
Alibaba
BABA
|
$2.59M |
| 4 |
XYZ
Block, Inc.
XYZ
|
$2.4M |
| 5 |
Intel
INTC
|
$2.07M |
Sector Composition
| 1 | Technology | 37.36% |
| 2 | Healthcare | 29.98% |
| 3 | Consumer Discretionary | 13.6% |
| 4 | Communication Services | 8.97% |
| 5 | Financials | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Kura Oncology
KURA
$732M
| $333K | 0.04% |
15,617
+7,027
| +82% | +$150K |
|
227
Marriott International Class A Common Stock
MAR
$72B
| $330K | 0.04% |
1,306
+723
| +124% | +$182K |
|
228
CSX Corp
CSX
$60.2B
| $328K | 0.04% |
8,837
+4,898
| +124% | +$182K |
|
229
Ardelyx
ARDX
$1.57B
| $327K | 0.04% |
44,754
+17,903
| +67% | +$131K |
|
230
Edgewise Therapeutics
EWTX
$1.54B
| $326K | 0.04% |
17,881
+10,543
| +144% | +$192K |
|
|
VRNA
231
Verona Pharma
VRNA
$9.18B
| $325K | 0.04% |
20,200
+5,322
| +36% | +$85.6K |
|
232
Protagonist Therapeutics
PTGX
$3.62B
| $324K | 0.04% |
11,192
+4,517
| +68% | +$131K |
|
233
NovoCure
NVCR
$1.35B
| $322K | 0.04% |
20,580
+8,217
| +66% | +$128K |
|
234
Veracyte
VCYT
$2.41B
| $320K | 0.04% |
14,447
+5,999
| +71% | +$133K |
|
|
INBX
235
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $318K | 0.04% |
9,106
+3,635
| +66% | +$127K |
|
236
Yum! Brands
YUM
$40.1B
| $317K | 0.04% |
2,285
| – | – |
|
237
Agios Pharmaceuticals
AGIO
$2.36B
| $315K | 0.04% |
10,780
+4,311
| +67% | +$126K |
|
238
Pfizer
PFE
$141B
| $315K | 0.04% |
+11,337
| New | +$315K |
|
239
Cintas
CTAS
$82.9B
| $314K | 0.04% |
1,828
+1,024
| +127% | +$176K |
|
240
Dynavax Technologies
DVAX
$1.19B
| $311K | 0.04% |
25,099
+10,143
| +68% | +$126K |
|
241
Snowflake
SNOW
$76.5B
| $307K | 0.04% |
+1,900
| New | +$307K |
|
242
4D Molecular Therapeutics
FDMT
$302M
| $305K | 0.04% |
9,579
+4,628
| +93% | +$147K |
|
243
O'Reilly Automotive
ORLY
$88.1B
| $300K | 0.04% |
3,990
+2,235
| +127% | +$168K |
|
|
FUSN
244
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $297K | 0.04% |
13,920
+5,544
| +66% | +$118K |
|
245
PACCAR
PCAR
$50.5B
| $293K | 0.04% |
2,363
+1,323
| +127% | +$164K |
|
246
ADMA Biologics
ADMA
$4.03B
| $290K | 0.04% |
43,870
+17,728
| +68% | +$117K |
|
247
Disc Medicine
IRON
$2.14B
| $289K | 0.04% |
4,641
+1,848
| +66% | +$115K |
|
248
NXP Semiconductors
NXPI
$57.5B
| $288K | 0.04% |
1,157
+647
| +127% | +$161K |
|
249
Bath & Body Works
BBWI
$6.3B
| $280K | 0.04% |
5,605
-13,700
| -71% | -$685K |
|
250
ANI Pharmaceuticals
ANIP
$2.06B
| $279K | 0.04% |
4,033
+1,666
| +70% | +$115K |
|